Aware Super Pty Ltd as trustee of Aware Super Purchases Shares of 60,696 IDEXX Laboratories, Inc. $IDXX

Aware Super Pty Ltd as trustee of Aware Super acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,696 shares of the company’s stock, valued at approximately $34,104,000.

Several other hedge funds also recently modified their holdings of IDXX. SHP Wealth Management bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $29,000. WealthCollab LLC bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in IDEXX Laboratories during the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $576.07 on Friday. The business’s 50-day simple moving average is $554.35 and its 200 day simple moving average is $600.17. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market cap of $45.44 billion, a price-to-earnings ratio of 42.42, a P/E/G ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $513.02 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the business posted $2.91 EPS. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on IDXX. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Finally, UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.